11-02/03 :: February / March 2011
presented include results of a survey of over 100 Ob- stetrician/Gynecologists and Primary Care Physicians regarding the need for an FDA-approved drug to tre- at a form of Female Sexual Dysfunction (FSD) known as Hypoactive Sexual Desire Disorder (HSDD).
With the Solid Injection by Air Stream (SIA) method from Bayer MaterialScience, the solids are transported in a gas stream and only injected into the mixing chamber during the blending phase. This method opens up entirely new possibilities for the use of composite materials, regardless of whether they are hard or soft, or if the polyurethane is a solid or a foam. One possible area of application is adding flame retardants to polyurethane parts, which is required for a variety of applications. © BMS
There are currently no FDA-approved therapeutic treatment options for women with HSDD. A signifi- cant number of physicians (over 90 percent) reported that they prescribe off-label testosterone for women to treat FSD, however, these physicians are dissa- tisfied with the non-FDA approved, off-label alter- natives. The physicians indicated that they hear an average of 37 unsolicited inquiries per month from women regarding sexual dysfunction. Nationally, it is estimated that 4.1 million off-label testosterone prescriptions are filled annually. http://www.biosantepharma.com
Gund Investment Corporation and existing investors Battelle Ventures, Innovation Valley Partners and KT Venture Group joining the round.
Furthermore, BioNanomatrix introduced the nano- Analyzer 1000 System at the 2010 Annual Meeting of the American Society of Human Genetics last Novem- ber and said that the company “has already placed a number of systems with early-access users.” http://www.bionanomatrix.com
ioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), a pharmaceutical company developing products
for the treatment of female sexual health, presented critical female sexual dysfunction market data at the ISSWSH (The International Society for the Study of Women’s Sexual Health) annual meeting. The data
arl Zeiss has been awarded a $22.6 million contract to develop certain nano manufacturing
and imaging applications based on its revolutionary ORION™ Gas Field Ion Source (GFIS) technology. The contract was awarded to US-based Carl Zeiss NTS, LLC by the Intelligence Advanced Research Projects Activity (IARPA) under the Circuit Analysis Tool (CAT) program.
The CAT program is geared towards addressing chal- lenges in nano manufacturing and imaging pertaining to circuit analysis for which existing techniques have no clear evolutionary path to the 22nm node and beyond. The nano manufacturing thrust of the CAT program is focused on the modification of the electri- cal behavior of an integrated circuit through the use of precise deposition and removal techniques that can cut and/or create new connections. The GFIS